A lthough improved medical therapies have led to an overall decrease in mortality from acute coronary events, myocardial infarction remains the leading cause of death in the United States. 1 Numerous studies have demonstrated that the immediate cause of acute coronary syndromes is atherosclerotic plaque disruption inducing platelet activation and acute thrombus formation. 2, 3 Atherosclerosis is a progressive disease in which inflammatory cells, activated smooth muscle cells, lipids, and extracellular matrix accumulate in the arterial wall resulting in growth of plaques. Atherosclerosis is now viewed as an inflammatory disease of the vascular system, with macrophages, lymphocytes, and platelets being important sources of cytokines and growth factors that control the migration, proliferation, and activation of smooth muscle cells and monocytes leading to intimal hyperplasia. 2, 4, 5 Recent data support a critical role of chemokines in the accumulation of macrophages and lipids in atherosclerotic lesions. 6 -8 Chemokines are a superfamily of chemotactic cytokines. 9, 10 They activate and direct the migration of leukocytes by binding to specific G protein-coupled 7-transmembrane cell surface receptors. 11 Expression of several chemokines, including monocyte chemoattractant protein (MCP)-1, MCP-4, RANTES (regulated on activation normal T-cell expressed and secreted), and interleukin-8 (IL-8) is increased in human atherosclerotic plaques compared with normal vessels. [12] [13] [14] [15] [16] In vivo animal studies using genetically modified mouse strains have revealed functional roles for MCP-1 and its receptor CCR2, 6, 7 and the murine homologue of the IL-8 receptor, CXCR2, 8 in monocyte recruitment and retention in atherosclerotic lesions, suggesting that chemokines and their receptors play a critical role in atherogenesis.
Platelets are anucleated cellular fragments that circulate in the blood. 17 In addition to their well-recognized role in hemostasis and acute thrombus formation, platelets are also thought to have proinflammatory and growth-regulatory properties that contribute to progression of atherosclerosis. 4, 18 Platelet activation releases multiple growth factors and inflammatory mediators, including chemokines, into the microenvironment. In fact, the first chemokine described, platelet factor 4, was identified as a heparin-binding protein released from activated platelets and has been used as an in vivo marker of platelet activation. 19, 20 Although platelets contain numerous other chemokines, 21, 22 previous work has not focused on the platelet as a target for chemokines.
Because platelets are in contact with cells that produce chemokines, we investigated the effect of chemokines on platelet aggregation and found that of the 16 chemokines tested stromal cell-derived factor-1 (SDF-1), a CXC chemokine and a known chemotactic factor for lymphocytes and monocytes, 23 induced platelet activation measured by aggregation and Ca 2ϩ flux. In addition, we found that SDF-1 protein was highly expressed in human atherosclerotic plaques but not in normal vessels. Our data suggest that SDF-1 may be involved in the pathology of atherosclerosis.
Materials and Methods

Blood Collection and Platelet Preparation
Human blood was collected from antecubital veins of healthy, male or female, aspirin-free volunteers into syringes containing heparin (10 U/mL final concentration) for flow cytometry studies and sodium citrate (0.38% final concentration) for aggregation studies or acid citrate dextrose (1.5 mL of acid citrate dextrose for 8.5 mL of blood) for Ca 2ϩ flux studies. Platelet-rich plasma (PRP) was prepared by centrifugation of whole blood at 150g for 15 minutes. Platelet-poor plasma was prepared by centrifugation of PRP at 1200g for 15 minutes.
Aggregation Studies
Experiments were performed using a Chrono-Log model 560vs or 490-2D aggregometer. Aliquots of PRP (0.50 or 0.45 mL each, with a platelet concentration of 1 to 3ϫ10 5 platelets/mL) were incubated at 37°C and stirred at 1000 rpm. Recombinant chemokines were obtained from PeproTech Inc, and SDF-1␤ was obtained from 2 different sources, PeproTech Inc and Genetics Institute. Aggregation was measured as a percentage change in optical density, with the instrument calibrated to yield 0% change in optical density for PRP and with the platelet-poor plasma 100% standard for change in optical density. Aggregation scale was set so that maximal aggregation gave 85% to 95% chart deflection. The aggregation data were presented as the maximum light transmittance of the sample after the addition of SDF-1 in the presence or absence of inhibitory antibodies (Abs) or chemical inhibitors. The data are expressed as meanϮSD. Inhibition experiments were done using a CXCR4 monoclonal Ab (mAb) 12G5 (R&D), goat anti-SDF-1 polyclonal Ab (R&D), pertussis toxin, wortmannin, LY294002, genistein, and aspirin (Sigma). DMSO was used as vehicle for wortmannin, LY294002 and genistein and 1N sodium hydroxide as vehicle for aspirin.
Flow Cytometry
Platelets were analyzed by flow cytometry using fixed whole blood as previously described. 24 Staining was performed with mouse anti-human CXCR4 mAbs MAB173 or 12G5 (R&D) followed by FITC-conjugated F(ab) 2 goat anti-mouse IgG (ImmunoTech) and phycoerythrin-conjugated mouse anti-human CD41a (anti-glycoprotein IIb) mAb (Pharmingen).
Ca
2؉ Flux
Fura-2-loaded platelets were prepared from acid citrate dextroseanticoagulated blood, as described previously. 25 PRP was collected by centrifugation for 15 minutes at 200g and 100 mol/L aspirin added. Platelets were then loaded with fura-2 by incubating PRP with 2 mol/L of acetoxymethyl ester of fura-2 (Molecular Probes, Inc) for 45 minutes at 37°C in the dark. PRP was then centrifuged at 1500g for 10 minutes and the pellet resuspended in a buffer containing (in mmol/L) NaCl 145, KCl 4, NaH 2 PO 4 1, MgCl 2 0.8, CaCl 2 1.8, HEPES 25, and glucose 22. Changes of cytosolic free calcium were determined after addition of SDF-1 (50 or 100 nmol/L) by monitoring the excitation fluorescence intensity emitted at 510 nm in response to sequential excitation at 340 and 380 nm using a Delta RAM (random access monochromator) fluorimeter (Photon Technology International). The data are presented as the relative ratio of fluorescence at 340/380 nm.
Western Blotting
Surgical specimens of human carotid atheroma and aorta were homogenized in a mixture of 20 mmol/L NaCl, 200 mmol/L Tris-HCl (pH 7.6), and 10% SDS. Extracts were separated (200 mg proteins per lane) by standard SDS-PAGE under reducing conditions and blotted onto polyvinylidene difluoride membranes (Bio-Rad) using a semidry blotting apparatus (0.8 mA/cm 2 , 30 minutes; Bio-Rad). Blots were blocked, and dilution of first and second Ab was made in 5% dry skim milk/PBS/0.1% Tween. After 1 hour of incubation with the primary goat anti-human SDF-1 Ab (R&D), blots were washed 3 times (PBS/0.1% Tween), and the secondary peroxidase-conjugated rabbit anti-goat Ab (Jackson ImmunoResearch) was added for another hour. Blots were washed 3 times, and detection of the antigen was carried out using the enhanced chemiluminescent detection method (Dupont-NEN).
Immunohistochemistry
Atherosclerotic plaques from human carotid arteries and nonatherosclerotic arteries were obtained at endarterectomy or from transplant donors or autopsies by protocols approved by the Human Investigation Review Committee at the Brigham and Women's Hospital. Serial cryostat sections (6 mm) were cut, air-dried onto microscope slides (Fisher Scientific), and fixed in acetone at -20°C for 5 minutes. Sections preincubated with PBS containing 0.3% hydrogen peroxidase activity were incubated (60 minutes) with the primary goat anti-human SDF-1 Abs (R&D and Santa Cruz Biotechnology) or control Ab, diluted in PBS supplemented with 5% appropriate serum. Finally, sections were incubated with the respective biotinylated secondary Ab (45 minutes, Vector Laboratories) followed by avidin-biotin-peroxidase complex (Vectastain ABC kit), and Ab binding was visualized with 3-amino-9-ethyl carbazole (Vector Laboratories). Cell types were characterized by double immunofluorescence staining using anti-muscle ␣-actin mAb specific for smooth muscle cells (Enzo Diagnostics), anti-CD31 mAb specific for endothelial cells (Dako), and anti-CD68 mAb specific for macrophages (Dako), using streptavidin conjugated by FITC (cell-specific Ab) and Texas Red (SDF-1␣ specific Ab).
Results
SDF-1 Induces Human Platelet Aggregation
We studied the in vitro aggregation of human platelets in response to 16 Chemokines were tested at 25, 40, and 100 nmol/L (each chemokine concentration was used in a different experiment). Of the chemokines tested, only SDF-1 induced platelet aggregation ( Figure 1A ). At all concentrations tested (25 to 100 nmol/L), the other chemokines did not induce platelet aggregation measured by the lumi-aggregometer.
SDF-1␣ and SDF-1␤ are CXC chemokines derived from a single SDF-1 gene by alternative splicing with SDF-1␤ containing an additional 3Ј exon encoding 4 C-terminal amino acids. 26, 27 The effect on platelets of SDF-1␣ and SDF-1␤ was concentration dependent (Figure 1B and 1C) . The concentration of SDF-1␣ and ␤ necessary to induce a maximum aggregatory response varied between experiments and was between 10 and 100 nmol/L.
Platelets have several levels of response to stimuli. 28 The first level consists of platelet shape change, seen as a minor change in aggregometer traces. Primary aggregation is the second level of response, defined as aggregation without secretion, and is at least partially reversible. Secondary aggregation, the third level of activation, is associated with Figure 1C) . Of 12 healthy donors tested, 10 had a full response to SDF-1 (primary and secondary phase of aggregation), whereas 2 had only a primary aggregatory phase. We also observed that SDF-1 induced a more robust aggregation when PRP was kept at 4°C
before the aggregation studies compared with room temperature or 37°C. These data suggest that other factors may regulate platelet responsiveness to SDF-1.
SDF-1 Induces Ca 2؉ Flux in Platelets
Because chemokines characteristically induce elevation in cytosolic Ca 2ϩ concentration in leukocytes, we tested the ability of SDF-1 to induce a similar response in platelets. Ca 2ϩ elevation in washed human platelets was reproducibly induced by 100 nmol/L SDF-1 (Figure 2 ). SDF-1 at 50 nmol/L had a minimal effect on Ca 2ϩ flux in platelets. ADP, a known platelet agonist, was used as a positive control for comparison. I-309, one of the other chemokines tested that did not induce platelet aggregation, was used as a negative control and had no effect on Ca 2ϩ flux in platelets.
CXCR4 Mediates the Effect of SDF-1 on Platelets
SDF-1 signals cells through the chemokine receptor CXCR4, 29,30 a 7-transmembrane-spanning G protein-coupled cell-surface glycoprotein. We found that human peripheral blood platelets expressed CXCR4 by flow cytometry using 2 different mAbs specific for CXCR4 (data not shown), which confirmed 3 recent reports. [31] [32] [33] A mAb to CXCR4 inhibited SDF-1-induced platelet aggregation by 84.4Ϯ2.4%, demonstrating that SDF-1 activates platelets through CXCR4 ( Figure 3A ). An isotype-matched control Ab had no effect on SDF-1-induced platelet aggregation. Also, pertussis toxin inhibited SDF-1-induced platelet aggregation by 83.9Ϯ6% ( Figure 3B ), confirming that this effect was at least in part mediated by a pertussis toxin-sensitive G protein, such as G␣i.
Anti-SDF-1 Ab Inhibits the Effect of SDF-1 on Platelet Aggregation
To confirm that SDF-1 was directly responsible for the observed effects on platelets, SDF-1 was incubated for 15 to 30 minutes with a neutralizing goat anti-SDF-1 polyclonal Ab before addition to the PRP. Preadsorption with the SDF-1 polyclonal Ab inhibited the SDF-1 effect on platelets by 92.9Ϯ2.7% (Figure 4 ).
Intracellular Signaling Pathways Involved in SDF-1-Induced Platelet Aggregation
In an attempt to identify the mechanism of SDF-1-induced platelet activation, we explored the signaling pathways involved in this process using a variety of known inhibitors. Aspirin is known to inhibit platelet cyclooxygenase and the second wave of ADP-induced platelet aggregation characterized by maximal irreversible aggregation, platelet granule secretion, and prostanoid synthesis. 17 Aspirin inhibited the SDF-1 effect on platelets by 70.1Ϯ3.9%. Aspirin inhibited the second but not the first wave of SDF-1-induced aggregation, suggesting a requirement for prostanoid synthesis in SDF-1-induced platelet aggregation ( Figure 5A ). Genistein, a tyrosine kinase inhibitor, decreased by 72.3Ϯ4.4% SDF-1-induced platelet aggregation. Genistein also completely inhibited the SDF-1-induced secondary phase of aggregation but not the primary phase (even at a 10 mmol/L concentration), indicating that the secondary phase of SDF-1-induced platelet aggregation appears to require tyrosine kinase activation. The maximal inhibitory effect of genistein was seen at a concentration of 200 to 800 mol/L ( Figure 5B ). Wortmannin and LY294002, 2 structurally unrelated PI 3-kinase inhibitors, 34 completely inhibited SDF-1-induced platelet aggregation. The inhibitory effect of wortmannin and LY29004 on SDF-1-induced platelet aggregation was concentration dependent ( Figure 5C ). Under our experimental conditions, a wortmannin concentration of 400 to 500 nmol/L was required to induce complete (100%) inhibition of SDF-1 effect on platelets. Because in the nanomolar range wortmannin can inhibit at least 2 other enzymes, namely, phosphatidylinositol 4-kinase and phospholipase A, 35 the effect of another PI-3 kinase inhibitor, LY29004, was also tested. LY92004 inhibited SDF-1-induced platelet aggregation in a dose-dependent manner, reaching complete inhibition of platelet aggregation at 50 mol/L ( Figure 5D ). Taken together, these data suggest that SDF-1-induced platelet aggregation likely involves PI-3 kinase and depends, at least in part, on both prostanoid synthesis and tyrosine kinases.
Atherosclerotic Plaques Express SDF-1 Protein
In view of the role of platelet activation in atherosclerosis and thrombosis, we investigated the expression of SDF-1 protein in normal human arteries and atherosclerotic plaques. Western blot analysis revealed a striking increase in SDF-1 immunoreactivity in atherosclerotic plaques isolated from 4 different carotid atheromas compared with nonatherosclerotic arteries (Figure 6 ). Immunohistochemical staining using 2 different anti-SDF-1-specific Abs showed abundant expression of SDF-1 protein in atheromatous arteries but not in normal arteries (Figure 7) . Double immunofluorescence colocalized SDF-1 expression in plaques to endothelial cells (CD31ϩ), smooth muscle cells (␣-actinϩ), and macrophages (CD68ϩ) (Figure 7) . 
Discussion
It is becoming increasingly clear that chemokines have other activities in addition to leukocyte chemotaxis. Mice deficient in SDF-1 and CXCR4 have defects in B-cell lymphopoiesis and bone marrow myelopoiesis and die perinatally with defects in cerebellar, cardiac, and vascular morphogenesis. 36 -39 SDF-1 and CXCR4 appear to be a monogamous receptor ligand pair, which is unusual for the chemokine system. SDF-1 is constitutively expressed in bone marrow stromal cells 27 and to date has not been shown to be upregulated in inflammatory diseases. Recently, SDF-1 was shown to increase megakaryocyte production in the presence of thrombopoietin 31 and to induce megakaryocyte chemotaxis and adhesion to endothelial cells. 31, 32 Our finding that SDF-1 is a potent activator of platelets has identified a novel activity for the chemokine family involving an important cell type not previously known to respond to chemokines.
SDF-1-induced platelet activation was measured by 2 different methods, platelet aggregation and Ca 2ϩ flux. Moreover, a mAb to CXCR4 reduced the SDF-1 effect on platelets by Ϸ84%, which is similar to previous inhibition studies reported with this anti-CXCR4 mAb. 40 Pertussis toxin also inhibited SDF-1-induced aggregation, suggesting that its effect on platelets is mediated via a pertussis toxin-sensitive G protein such as G␣i. The complete inhibition of the effect of SDF-1 on platelets by wortmannin and LY29004 strongly suggests the involvement of PI-3 kinase in the initial primary phase of aggregation. In contrast, the inhibition of only the secondary wave of SDF-1-induced platelet aggregation by genistein suggests the need for tyrosine kinases to achieve maximal irreversible aggregation and platelet granule secretion after CXCR4 activation. These data are consistent with the previous reports suggesting that PI-3 kinase acts upstream of tyrosine kinases in the SDF-1 signal transduction pathway. 41 The SDF-1-induced secondary wave of platelet aggregation was inhibited by aspirin, suggesting the involve- 33 are not readily apparent, but they may have to do with methods of platelet collection and handling. Our finding that SDF-1 induces platelet activation was seen in Ͼ24 independent experiments using 13 different blood donors. We have also used 3 different recombinant SDF-1 preparations from 2 different manufacturers and have consistently observed SDF-1-induced platelet aggregation. Furthermore, we observed Ϸ93% inhibition of SDF-1 effect on platelets by preadsorption with a neutralizing SDF-1 Ab. Therefore, we believe that it is exceedingly unlikely that a contaminant in our SDF-1 preparations accounts for the activity we have observed. In addition, in our studies SDF-1 induced Ca 2ϩ fluxes in washed platelets, making it unlikely that another plasma-derived factor interacting with SDF-1 was responsible for activating the platelets. Thus, we have established that SDF-1 can activate platelets.
Platelets play a critical role in hemostasis and participate in the pathophysiology of important thrombo-occlusive diseases, such as myocardial infarction, a leading cause of death, which is increasing in worldwide prevalence. 1 Coronary thrombosis, the immediate cause of acute coronary syndromes, usually results from atherosclerotic plaque disruption and in situ platelet aggregation. [1] [2] [3] 5 Plaque rupture or erosion is associated with vascular endothelium damage, which changes the normally antithrombotic vessel into a prothrombotic surface partly through the exposure of subendothelial structures and perhaps also as a result of a local decrease in the production of platelet antagonists, such as endothelial cell-derived nitric oxide and prostacyclin. 42 Our findings that SDF-1 localizes within atherosclerotic plaques and induces platelet aggregation suggest that SDF-1 may play a role in the formation of a platelet-rich thrombus after plaque disruption.
The activated platelet may also contribute to the local inflammatory response at their site of activation and may therefore contribute to the development of atherosclerosis. 18 Activated platelets release their own proinflammatory cytokines, chemokines, and lipid metabolites. 4, 17, 21 In addition, activated platelets express the CD40 ligand and P-selectin, which induce the secretion of chemokines from endothelial cells and monocytes, respectively. 43, 44 These pathways serve to amplify the inflammatory response at vessel sites where platelets become activated, such as sites of vascular endothelial damage or plaque rupture. Atherosclerotic plaques also contain another chemokine, MCP-1, a potent monocyte chemoattractant. 12, 13 Recent studies using mice deficient in MCP-1 and its receptor, CCR2, have revealed an important role for MCP-1 in the early recruitment of monocytes into the vessel wall and subsequent lipid deposition and lesion formation in murine models of atherosclerosis. 6, 7 However, in both mutant mouse strains, the recruitment of monocytes into nascent atherosclerotic lesions was only partially reduced, suggesting that other factors contribute to monocyte recruitment and lesion formation. In addition to the activity we have described for SDF-1 on platelets, SDF-1 is a potent chemotactic factor for T cells and monocytes 23 and can arrest circulating lymphocytes. 45 Because monocytes, lymphocytes, and platelets are involved in the pathogenesis of atherosclerosis, plaque rupture, and acute thrombus formation, inhibiting SDF-1-CXCR4 signaling could prove beneficial for the treatment of atherosclerosis.
